Celldex Therapeutics, Inc. (NASDAQ:CLDX) VP Sells $525,900.00 in Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDXGet Free Report) VP Elizabeth Crowley sold 15,000 shares of the business’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $35.06, for a total transaction of $525,900.00. Following the transaction, the vice president now directly owns 9,074 shares in the company, valued at $318,134.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Elizabeth Crowley also recently made the following trade(s):

  • On Thursday, May 30th, Elizabeth Crowley sold 38,597 shares of Celldex Therapeutics stock. The stock was sold at an average price of $33.64, for a total value of $1,298,403.08.

Celldex Therapeutics Trading Up 1.2 %

CLDX stock opened at $36.43 on Friday. The firm has a fifty day moving average price of $37.86 and a two-hundred day moving average price of $38.82. Celldex Therapeutics, Inc. has a 1-year low of $22.11 and a 1-year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Equities research analysts expect that Celldex Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Strs Ohio lifted its holdings in shares of Celldex Therapeutics by 92.9% in the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 1,300 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics in the first quarter worth $147,000. CANADA LIFE ASSURANCE Co lifted its stake in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 955 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 1,582 shares during the period. Finally, Aigen Investment Management LP bought a new position in shares of Celldex Therapeutics during the fourth quarter worth about $251,000.

Wall Street Analyst Weigh In

Several research firms have issued reports on CLDX. Guggenheim lifted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Wolfe Research initiated coverage on shares of Celldex Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $51.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Friday, March 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

Read Our Latest Stock Report on Celldex Therapeutics

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Recommended Stories

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.